Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer

Irene Stasi, Federico Cappuzzo Medical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy Abstract: Bavituximab is a an unconjugated, chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the phosphatidylserine (PS) expressed on tumor endothelium, with a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stasi I, Cappuzzo F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d9d9c846c2464aea9def0e29644841ac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d9d9c846c2464aea9def0e29644841ac
record_format	dspace
spelling	oai:doaj.org-article:d9d9c846c2464aea9def0e29644841ac2021-12-02T05:49:58ZProfile of bavituximab and its potential in the treatment of non-small-cell lung cancer1179-2728https://doaj.org/article/d9d9c846c2464aea9def0e29644841ac2014-08-01T00:00:00Zhttp://www.dovepress.com/profile-of-bavituximab-and-its-potential-in-the-treatment-of-non-small-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728 Irene Stasi, Federico Cappuzzo Medical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy Abstract: Bavituximab is a an unconjugated, chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the phosphatidylserine (PS) expressed on tumor endothelium, with a specific mechanism of action. PS is an anionic membrane phospholipid, physiologically restricted to the internal membrane leaflet; various pathophysiologic processes cause the exposure of PS on the external membrane leaflet. Bavituximab, once bound, starts up host effector activities, such as antibody dependent cellular cytotoxicity, causing vessel destruction and enhancing antitumor immunity. Phase I clinical trials of bavituximab administered as monotherapy or in combination with other chemotherapeutic agents in adults with pretreated solid tumors have been accomplished, indicating that bavituximab can be safely dispensed weekly, with a recommended dose of 1 and 3 mg/kg. A Phase II randomized, placebo-controlled trial of bavituximab plus docetaxel, in the second-line therapy setting of locally advanced or metastatic non-small-cell lung cancer, has been conducted and recently presented, suggesting a clinical benefit of the combination, with an overall response rate of 17% and median overall survival of more than 11 months. A Phase III trial is currently ongoing. Bavituximab has been studied in combination with platinum-based doublets with promising results. In the present paper we summarize the preclinical development and clinical experience with bavituximab in non-small-cell lung cancer. Keywords: bavituximab, NSCLC, targeted therapy, vascular disrupting agent, vascular targeting agentStasi ICappuzzo FDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 43-50 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Stasi I Cappuzzo F Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
description	Irene Stasi, Federico Cappuzzo Medical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy Abstract: Bavituximab is a an unconjugated, chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the phosphatidylserine (PS) expressed on tumor endothelium, with a specific mechanism of action. PS is an anionic membrane phospholipid, physiologically restricted to the internal membrane leaflet; various pathophysiologic processes cause the exposure of PS on the external membrane leaflet. Bavituximab, once bound, starts up host effector activities, such as antibody dependent cellular cytotoxicity, causing vessel destruction and enhancing antitumor immunity. Phase I clinical trials of bavituximab administered as monotherapy or in combination with other chemotherapeutic agents in adults with pretreated solid tumors have been accomplished, indicating that bavituximab can be safely dispensed weekly, with a recommended dose of 1 and 3 mg/kg. A Phase II randomized, placebo-controlled trial of bavituximab plus docetaxel, in the second-line therapy setting of locally advanced or metastatic non-small-cell lung cancer, has been conducted and recently presented, suggesting a clinical benefit of the combination, with an overall response rate of 17% and median overall survival of more than 11 months. A Phase III trial is currently ongoing. Bavituximab has been studied in combination with platinum-based doublets with promising results. In the present paper we summarize the preclinical development and clinical experience with bavituximab in non-small-cell lung cancer. Keywords: bavituximab, NSCLC, targeted therapy, vascular disrupting agent, vascular targeting agent
format	article
author	Stasi I Cappuzzo F
author_facet	Stasi I Cappuzzo F
author_sort	Stasi I
title	Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
title_short	Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
title_full	Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
title_fullStr	Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
title_full_unstemmed	Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
title_sort	profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/d9d9c846c2464aea9def0e29644841ac
work_keys_str_mv	AT stasii profileofbavituximabanditspotentialinthetreatmentofnonsmallcelllungcancer AT cappuzzof profileofbavituximabanditspotentialinthetreatmentofnonsmallcelllungcancer
_version_	1718400262067978240

Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer

Ejemplares similares